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Abstract
Background—In sub-Saharan Africa, liver disease epidemiology among HIV-infected 
individuals is not well described, in part due to limited access to diagnostic tests for liver fibrosis.
Methods—We recruited HIV-infected adults (≥18 years) at antiretroviral therapy initiation at two 
facilities in Zambia’s capital Lusaka. Using vibration controlled transient elastography we 
assessed liver stiffness, a surrogate for fibrosis/cirrhosis, and analyzed liver stiffness measurements 
(LSM) according to established thresholds (>7.0 kPa for significant fibrosis and >11.0 kPa for 
cirrhosis). All participants underwent standardized screening for potential causes of liver disease 
including chronic hepatitis B (HBV) and C virus co-infection, herbal medicine, and alcohol use. 
We used multivariable logistic regression to identify factors associated with elevated liver stiffness.
Results—Among 798 HIV-infected patients, 651 had a valid LSM (median age, 34 years; 53% 
female). HBV co-infection (12%) and alcohol use disorders (41%) were common and hepatitis C 
virus co-infection (<1%) was rare. According to LSM, 75 (12%) had significant fibrosis and 13 
(2%) had cirrhosis. In multivariable analysis, HBV co-infection as well as male sex, increased age, 
and WHO clinical stage 3 or 4 were independently associated with LSM >7.0 kPa (all P<0.05). 
HBV co-infection was the only independent risk factor for LSM >11.0 kPa. Among HIV-HBV 
patients, those with elevated ALT and HBV viral load were more likely to have significant liver 
fibrosis than patients with normal markers of HBV activity.
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Conclusions—HBV co-infection was the most important risk factor for liver fibrosis and 
cirrhosis and should be diagnosed early in HIV care to optimize treatment outcomes.
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Introduction
In high-income settings advanced liver disease is a leading cause of mortality among HIV-
infected individuals, primarily due to chronic viral hepatitis co-infection. In the D:A:D study 
of HIV-infected patients taking antiretroviral drugs in Europe, Australia, and Argentina, 
14.5% of deaths were liver disease-related as a result of decompensated cirrhosis, and/or 
hepatocellular carcinoma.1 Among those who died from liver disease, 17% had chronic 
hepatitis B virus (HBV) and 66% had hepatitis C virus (HCV).1 In the Multicenter AIDS 
Cohort Study in the United States, men who were dually HIV- and HBV-infected had 8 
times increased liver-related mortality compared to those with HIV alone.2,3
HIV-infected individuals in sub-Saharan Africa (SSA) may have an increased risk of 
developing liver fibrosis and cirrhosis from various factors. In SSA, the prevalence of HBV 
co-infection reaches 10–15% in the general population and three million individuals are 
estimated to be dually infected with HIV and HBV.4 In these settings, chronic HBV is most 
commonly acquired in early childhood and was inconsistently found to be a risk factor for 
liver fibrosis.5,6 Fibrosis may also be caused by environmental exposure to aflatoxins and by 
certain traditional herbal medicines. In rural Uganda, for example, HIV-infected patients 
who reported herbal medicine use had 2–5 fold increased rates of liver fibrosis.7 
Schistosomiasis is also endemic in SSA and contributes to the burden of periportal fibrosis 
and portal hypertension.8
Due to limited access to diagnostic tests for liver fibrosis/cirrhosis in SSA, the causes of 
liver disease are poorly characterized among HIV-infected populations. Although the most 
advanced cases are diagnosed clinically, the diagnosis historically required a liver biopsy, 
which is unavailable outside of major referral centers due to its invasive nature, requirement 
for a pathologist to interpret hepatic histology, and potential risk of complications. To reduce 
the need for biopsy, blood and imaging tests for liver fibrosis have been developed, including 
transient elastography (TE, Fibroscan®), which has been used in several recently published 
studies in Africa5,9,10 and recommended by the World Health Organization in management 
of HBV11 and HCV.12 Using TE, we measured liver stiffness in a relatively large cohort of 
HIV-infected, antiretroviral therapy (ART)-naïve Zambian adults and investigated possible 
risk factors for liver fibrosis/cirrhosis.
Methods
Study setting and patients
In two public sector HIV treatment facilities in Zambia’s capital Lusaka we recruited HIV-
infected adults (18+ years old) who were eligible for ART into a prospective cohort study. 
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According to local guidelines at the time, patients were ART eligible if they had WHO 
clinical stage 3 or 4 disease and/or a CD4+ count of <350 cells/mm3 prior to April 2014 
after which eligibility expanded to all patients with a CD4+ count <500 cells/mm3.13 
Patients who intended to transfer care to a facility outside of Lusaka within 12 months of 
ART initiation were excluded from participation. This study was implemented within the 
framework of the International Epidemiologic Databases to Evaluate AIDS in Southern 
Africa (IeDEA-SA), a large regional network of HIV treatment programs that pools and 
analyzes standardized and anonymized datasets.14 The ethics committees of the University 
of Zambia (Lusaka, Zambia) and University of North Carolina at Chapel Hill (North 
Carolina, USA) approved this study (clinicaltrials.gov identifier NCT02060162) and all 
patients provided informed consent prior to participation.
Laboratory measurements
In addition to WHO staging and CD4+ testing at enrollment, we measured height, weight, 
ALT, AST, creatinine, and platelet count. Using rapid point-of-care tests in the clinic we 
screened patients for hepatitis B surface antigen (HBsAg; Determine HBsAg, Alere Inc., 
Massachusetts, USA) using finger prick sampling and for anti-hepatitis C antibody 
(Oraquick HCV, Orasure Technologies, Pennsylvania, USA) using an oral swab kit. Patients 
were defined as HBV co-infected if the HBsAg test was positive. Among HBV co-infected 
individuals, we measured hepatitis B e antigen (HBeAg) and HBV DNA levels (Roche 
COBAS AmpliPrep/COBAS TaqMan HBV Test version 2.0; limit of detection, 20 IU/ml). 
We also determined HBV genotype using an in-house Sanger sequencing assay.15–17 
Nucleotide sequences were analyzed with Sequencher version 5.0 (Gene Codes Corporation, 
Michigan, USA) and the Geno2Pheno (www.geno2pheno.org) platform was used to predict 
HBV genotypes.
Assessment of liver stiffness
Liver fibrosis/cirrhosis was assessed in non-pregnant patients using TE according to 
manufacturer guidelines (Echosens, Paris, France). With patients lying supine with their 
right arm abducted, at least 10 valid liver stiffness measurements (LSM) were made of the 
right lobe of the liver. Measurements were made by 1 of 3 operators who received 
manufacturer-recommended training. We classified TE as very reliable if the interquartile 
range divided by median (IQR/M) was <0.1, reliable if IQR/M was 0.1–0.3, and poorly 
reliable if IQR/M was >0.3.18 We defined significant hepatic fibrosis (corresponding to 
Metavir stages F2–F4) as median LSM >7 kPa and cirrhosis (Metavir stage F4) as median 
LSM >11 kPa. These thresholds were suggested in the WHO guidelines for treatment of 
hepatitis B virus in resource-limited settings.11 In secondary analyses we considered high 
LSM thresholds (>9.3 kPa for significant fibrosis and >12.3 kPa for cirrhosis) that were used 
in other liver fibrosis studies in SSA and based on validation studies in Europe and the 
U.S.5,9
Other study procedures
Using a standardized questionnaire we screened for potential causes of elevated liver 
stiffness including anti-tuberculosis treatment, current herbal medicine use, regular exposure 
to freshwater lakes or rivers (a surrogate for schistosomiasis), and alcohol use. We assessed 
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current and recent alcohol consumption using the World Health Organization’s Alcohol Use 
Disorders Identification Test consumption questions (AUDIT-C),19 an instrument that has 
been used in other African settings.20 Each alcoholic beverage was standardized to a local 
beer that contained 10 grams of alcohol per 12-ounce bottle. We defined a possible alcohol 
use disorder as an AUDIT-C score of ≥3 points for women and ≥4 for men.19
Statistical analyses
Among patients with a valid TE result, we compared baseline characteristics between 
HBsAg positive and negative participants using Wilcoxon rank sum tests for continuous 
variables and Chi square tests for categorical ones. We categorized body mass index as 
<18.5, 18.5–25, and >25 and CD4+ count as <100, 100–199, 200–350, and >350 cells/mm3. 
We investigated the association between HBsAg-positivity and significant fibrosis and 
cirrhosis using multivariable logistic regression, adjusted for all factors associated with 
fibrosis or cirrhosis in univariable analyses as well as those identified a priori from literature 
review. Among HIV-HBV co-infected patients, we described the proportion with hepatic 
fibrosis and cirrhosis according to HBV viral load and ALT level. We used Stata version 12 
(Statacorp, College Station, Texas) for data analysis.
Results
From October 2013 to August 2014, we enrolled 798 HIV-infected treatment-naïve adults in 
the cohort study and 653 had TE at enrollment. The main reasons for a missing TE result 
were pregnancy as a contraindication (n=25), or enrollment at time when the instrument was 
unavailable (n=118). TE was invalid in two cases with the remaining 651 (82%) comprising 
the analysis cohort. Patients excluded from the analyses because of unavailability of TE had 
similar age, sex, WHO clinical stage, HBsAg status, and CD4+ count compared to those 
who received the test (all P>0.05).
Within the analysis cohort, the median age of participants was 34 years (interquartile range 
[IQR] 29–40), 343 (52.7%) were women, and the median CD4+ count was 229 cells/mm3 
(IQR 122–336) at the time of ART initiation. HBsAg-positivity was relatively common 
(n=98, 12.4%) but anti-hepatitis C antibody positivity was rare (n=1, <1%). No current or 
recent alcohol consumption (i.e., AUDIT-C score of 0) was reported by 360 (55.1%), 
moderate consumption (AUDIT-C of 1–2 for women and 1–3 for men) was reported by 25 
(3.8%), and 268 (41.2%) reported levels of drinking consistent with a possible alcohol use 
disorder (58.9% of men versus 25.2% of women, P<0.001). Current use of at least one 
herbal medicine was reported by 103 (15.8%) participants. A full description of the 
characteristics of the analysis cohort is displayed in Table 1.
Among HBV co-infected patients, 19 (29.7%) were hepatitis B e antigen positive, the 
median HBV viral load was 3.7 (2.1–6.4) log10 IU/ml, and 53.6% had HBV viral loads 
>2,000 IU/ml. HBV genotype was A1 for 29 patents, E for 28 patients, and 1 patient had 
mixed infection with A1 and E. Compared to their HBsAg-negative counterparts, HBV co-
infected patients were more likely to be male, to have alcohol use disorder, had higher 
median ALT but similar median CD4+ counts. Age and sex distribution were similar in both 
study groups (Table 1).
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Across the 651 assessments of liver stiffness, based on IQR/M, TE was very reliable in 357 
(54.8%), reliable in 289 (44.4%), and poorly reliable in 5 (0.8%). Median LSM was 5.1 kPa 
(IQR 4.4–6.1), 75 (11.5%) had LSM >7 kPa consistent with significant hepatic fibrosis, and 
13 (2.0%) had LSM >11 kPa consistent with cirrhosis. The proportion with significant 
fibrosis according to patient demographics and selected clinical characteristics are displayed 
in Figure 1. Patients who reported hazardous levels of alcohol consumption had similar 
median LSM (5.2 kPa) and a similar percentage with LSM >7.0 (11.7%) compared to non-
drinkers (median LSM, 5.0 kPa; 11.2%). In multivariable analyses, HBsAg-positivity was 
associated with the presence of significant liver fibrosis (adjusted odds ratio [AOR] 2.84; 
95% confidence interval [CI], 1.48–5.46). Other risk factors for LSM >7 kPa included age 
40+, male sex, and WHO clinical HIV stage 3 or 4 (all P<0.05). HBsAg-positivity was the 
only statistically significant predictor of cirrhosis (AOR 7.31; 95% CI, 2.14–24.59; Table 2). 
At thresholds of LSM >9.3 for significant fibrosis and >12.3 for cirrhosis, point estimates in 
the models were similar (Supplementary table), but only HBsAg-positivity remained 
significantly associated with the outcomes.
Among HBV co-infected patients, significant fibrosis was more common in those with 
elevated ALT (23.6% versus 8.8%, P=0.083), positive HBeAg (42.1% versus 22.2%, 
P=0.08), or HBV viral loads >20,000 IU/ml (31.2% versus 20.4%, P=0.32). When stratified 
by ALT levels (normal or elevated) and HBV viral load (≤20, 20–2,000, or >2,000 IU/ml), 
we observed a significant trend toward higher liver stiffness level with increases in both 
(P=0.04; Figure 2).
Discussion
Among HIV-infected patients in Lusaka, Zambia, HBsAg-positivity was a strong predictor 
of liver fibrosis and cirrhosis at the time of ART initiation and this association increased 
with markers of HBV severity. Increased age, male sex, and advanced clinical stage of HIV 
infection were also linked with elevated liver stiffness. These data suggest that HBV co-
infection should be diagnosed early during HIV care and that interventions to identify and 
manage liver disease in HIV programs in SSA could be tailored to specific groups.
Our findings are consistent with those of other African studies. At a public facility in 
Nigeria, 325 HIV-infected adult patients (including 93 with HIV-HBV) underwent a cross-
sectional assessment of liver fibrosis using TE.5 HIV-HBV co-infected patients had 5 times 
the odds of significant fibrosis compared to those with HIV alone. Similar to our findings, 
HBV viral load was a strong correlate of elevated stiffness measurement, supporting 
recommendations that HIV-HBV patients be treated with ART regimens that contain 
tenofovir, the most potent anti-HBV drug available.21 More recently, among 106 HIV-HBV 
patients taking lamivudine-based ART in Ghana, 24 (22.6%) had advanced fibrosis or 
cirrhosis by TE. Most patients were switched to a tenofovir-containing regimen and during 8 
months of follow-up, levels of liver stiffness decreased,10 suggesting a potential role for TE 
in longitudinal assessment of liver disease where the device is available.
In addition to HBV, we observed that men were more likely to have elevated liver stiffness. 
Women may have had relatively lower liver stiffness because of the protective effects of 
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estrogen in hepatic fibrogenesis.22 Although alcohol abuse disorders were not linked to LSM 
in the study, men were more likely to report alcohol use and this could explain their 
doubling of fibrosis compared to women. Worldwide alcohol is a leading cause of cirrhosis; 
however, in our cohort an elevated AUDIT-C score was not linked with liver stiffness for 
several potential reasons. First, in our experience, quantifying an individual’s alcohol intake 
in Zambia can be challenging because the most common form of alcohol, maize/sorghum 
beer, can have variable alcohol concentration and drinks are shared within a group.23 
Further, in our study, assessment of alcohol use was done at the time of ART initiation and 
we suspect that many recent drinkers had abstained for a period of weeks to months as they 
were HIV tested, linked to care, and assessed for ART eligibility. Therefore, the hepatic 
effects of heavy drinking such as steatohepatitis may have receded prior to our assessment of 
liver fibrosis. Despite these results, screening for alcohol use disorders remains an important 
intervention as heavy drinking was highly prevalent.
This study had a number of strengths. First, we demonstrated the feasibility of screening for 
liver fibrosis and cirrhosis using TE, a relatively novel non-invasive test that has been used 
in a very limited number of studies in SSA.5,9,10,24 Despite limited availability in SSA, 
WHO guidelines for HBV11 and HCV12 treatment in LMIC recommend TE for fibrosis 
staging when available. Our sample was recruited among treatment naïve patients at two 
large clinics in Lusaka and the data are likely representative of other urban populations in 
the region. Another strength of the study was comprehensive screening of hepatitis C virus, 
traditional/herbal medicine use, and alcohol abuse disorders. Finally, detailed analyses of the 
virologic and serologic characteristics of HBsAg-positive individuals added to the limited 
available literature on HIV-HBV in this region.
Our study also had weaknesses. Because of pregnancy and unavailability of TE, nearly 20% 
of our cohort did not have a baseline assessment of LSM. However, we do not expect this to 
have significantly biased our analyses as there were no major differences in the baseline 
characteristics of these patients compared to those analyzed. Although it is widely 
recommended for liver fibrosis assessment, TE is imperfect and has not been validated in 
HIV-infected cohorts in SSA. Rather than focus our analysis on the prevalence of fibrosis/
cirrhosis, we investigated risk factors for high LSM, considering various thresholds. We 
believe this approach provided evidence regarding the usefulness of TE in SSA settings. For 
settings where TE is not available, more investigation is needed into blood indices that 
depend on low cost tests, such as AST-to-platelet ratio,6,25 FIB-4,26 and GGT-to-platelet 
ratio.27 Finally, we did not comprehensively assess patients for other potential causes of liver 
fibrosis such as hepatosplenic schistosomiasis or aflatoxin exposure.
In summary, among treatment naïve HIV-infected adults in Lusaka, Zambia, HBV co-
infection was the most important risk factor for elevated liver stiffness. Liver-related 
mortality among HIV-infected individuals is often preceded by fibrosis and cirrhosis. 
Therefore, among HIV-HBV patients, liver fibrosis assessment using TE or other non-
invasive tests may be considered a viable technique to optimize care of this at risk group.
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FIGURE 1. 
Proportion of individuals with elevated liver stiffness, stratified by baseline characteristics
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FIGURE 2. 
Liver stiffness score according to markers of hepatitis B virus (HBV) severity among 81 
HIV-HBV co-infected patients
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Table 1
Sociodemographic and clinical characteristics of 651 HIV-infected Zambian adults with a valid liver stiffness 
measurement at the time of antiretroviral therapy initiation
Age, years
HBsAg-negative (n=570) HBsAg-positive (n=81) P value
34 (30–40) 34 (28–39) 0.48
Female sex 307 (53.9) 35 (43.2) 0.07
Education level
 None to grade 6 137 (24.1) 17 (21.2) 0.78
 Grades 7–12 422 (74.2) 61 (76.2)
 College/University 10 (1.8) 2 (2.5)
Body mass index 20 (18–22) 20 (19–23) 0.19
WHO clinical stage
 1 or 2 291 (51.5) 45 (56.2) 0.43
 3 or 4 274 (48.5) 35 (43.8)
Tuberculosis 95 (16.7) 12 (14.8) 0.67
CD4+ count, cells/mm3 226 (121–331) 233 (128–378) 0.48
Anti-HCV positive 0 (0) 1 (1.2) —
ALT, U/L 19 (14–27) 23 (13–40) 0.02
AST, U/L 31 (25–41) 35 (26–60) 0.06
HBeAg positive — 19 (30.0) —
HBV viral load, log IU/ml — 3.7 (2.1–6.4) —
Herbal medicine use 88 (15.4) 15 (18.5) 0.48
Alcohol consumptionb
 None 324 (56.8) 34 (42.0) 0.04
 Moderate 20 (3.5) 5 (6.2)
 Alcohol use disorder 226 (39.7) 42 (51.8)
Occupational fishing 132 (23.2) 27 (33.3) 0.05
All values are median (interquartile range) or number (%).
bAlcohol consumption was defined by consumption questions from Alcohol Use Disorders Identification Test (AUDIT-C). No drinking was 
defined as AUDIT-C score of 0, moderate drinking was AUDIT-C score of 1–2 for women and 1–3 for men, and alcohol use disorder was AUDIT-
C score of 3–12 for women and 4–12 for men.
Abbreviations: HBsAg, hepatitis B surface antigen; WHO, World Health Organization; HCV, hepatitis C virus; ALT, alanine aminotransferase; 
AST, aspartate aminotransferase; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus
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Table 2
Risk factors for significant fibrosis (>7.0 kPa) and cirrhosis (>11.0 kPa) based on transient elastography 
among HIV-infected Zambian adults
Significant fibrosis Cirrhosis
Crude OR (95% CI) Adjusted OR (95% CI) Crude OR (95% CI) Adjusted OR (95% CI)
Age, years
 18–29 Reference Reference Reference Reference
 30–39 2.22 (1.14–4.35) 1.94 (0.91–4.13) 1.46 (0.37–5.72) 2.01 (0.38–10.57)
 40+ 2.60 (1.27–5.32) 2.80 (1.26–6.24) 1.09 (0.22–5.49) 1.47 (0.21–10.08)
Sex
 Female Reference Reference Reference Reference
 Male 3.43 (2.03–5.79) 2.94 (1.61–5.39) 3.77 (1.03–13.83) 2.81 (0.66–11.96)
Body mass index
 18.5 and above Reference Reference Reference Reference
 <18.5 1.31 (0.77–2.24) 1.26 (0.69–2.31) 2.24 (0.72–6.94) 2.29 (0.63–8.31)
WHO clinical stage
 1 or 2 Reference Reference Reference Reference
 3 or 4 1.90 (1.04–3.48) 1.76 (0.97–3.22) 6.31 (1.39–28.68) 4.09 (0.76–21.86)
Tuberculosis 2.04 (1.18–3.51) 1.27 (0.66–2.04) 2.31 (0.70–7.64) 1.74 (0.48–6.32)
HBsAg-positive 2.34 (1.32–4.13) 2.84 (1.48–5.46) 5.82 (1.91–17.70) 7.31 (2.14–24.59)
CD4+ count, cells/mm3
 200+ Reference Reference Reference Reference
 <200 1.54 (0.95–2.49) 1.19 (0.70–2.04) 0.77 (0.25–2.38) 0.40 (0.11–1.44)
Alcohol use disorder 1.04 (0.65–1.68) 0.67 (0.38–1.18) 0.63 (0.19–2.06) 0.36 (0.09–1.39)
Occupational fishing 2.03 (1.23–3.59) 1.57 (0.90–2.75) 2.72 (0.90–8.21) 2.30 (0.70–7.62)
Herbal medicine use 1.26 (0.67–2.38) 1.34 (0.69–2.62) 0.44 (0.05–3.40) 0.37 (0.04–3.17)
Abbreviations: kPa, kilopascals; OR, odds ratio; WHO, World Health Organization
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